Guardant health analyst coverage
WebOct 18, 2024 · In the wake of Guardant Health, Inc.'s (NASDAQ:GH) latest US$536m market cap drop, institutional owners may be forced to take severe actions. Simply Wall St. Mar-10-23 08:05AM. Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield blood test. Business Wire -7.16%. WebFeb 26, 2024 · It can also be useful to step back and take a broader view of how analyst forecasts compare to Guardant Health's performance in recent years. It's pretty clear that analysts expect Guardant Health ...
Guardant health analyst coverage
Did you know?
WebFintel reports that on April 13, 2024, Canaccord Genuity initiated coverage of Verve Therapeutics (NASDAQ:VERV) with a Buy recommendation. Analyst Price Forecast Suggests 176.94% Upside As of ... WebNov 7, 2024 · Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2024. This would be a sizeable 39% improvement in sales compared to the last 12 months.
Web1 day ago · Guardant Health Shares Rise 8% After Biopsy Test Gets New Coverage Feb. 8, 2024 at 12:40 p.m. ET Guardant Health Gets FDA Approval for Guardant360 CDx as Companion Diagnostic for Orserdu WebNov 7, 2024 · View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting …
WebMar 1, 2024 · Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced … WebOct 6, 2024 · Guardant Health (GH 2.31%) did relatively well on the market Thursday. The cancer-diagnostics company's shares effectively traded sideways on a day when the S&P 500 index flopped by over 1%.
WebOct 19, 2024 · Today's Change. (0.62%) $0.15. Current Price. $24.33. Price as of March 27, 2024, 10:00 a.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...
WebOct 19, 2024 · NEW YORK – Investment bank Craig-Hallum on Wednesday initiated coverage of liquid biopsy firm Guardant Health with a Buy rating and a price target of $88. In a research note, analyst Alexander Nowak argued that the company's 10 years in the market are "just a precursor" to its future potential. grin on faceWebMar 7, 2024 · Guardant Health, Inc is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and … grin of the darkWebApr 13, 2024 · A number of analysts recently commented on the company. Citigroup lowered Guardant Health from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $60.00 ... grinold and kahn pdfWebGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. fight in applebees south carolinaWebFeb 8, 2024 · Guardant360 CDx test is now covered under UHC commercial policies for all FDA-approved biomarker confirmation indications in patients with advanced or metastatic breast or non-small cell lung... grinold chapterWebMar 7, 2024 · Guardant Health, Inc. (NASDAQ:GH - Get Rating) has received a consensus rating of "Moderate Buy" from the fifteen research firms that are currently covering the firm, MarketBeat reports.One analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price … fight in asdagrin on me 2 lyrics